investment

Kemira Expands Sizing Agents in China

Taiwan’s CPC Looks to Invest in US Shale

Ineos Plans Major Olefins Projects in Europe

Lubrizol Hikes Drug Product Manufacturing Capacity

Eastman Expands US Films Capacity

Kazakhstan and UAE Link on PE Project

Iran: Rediscovering a Sleeping Giant

China’s Wanhua Plans MDI Complex in Louisiana

Chinese Firms Eye Chemicals JVs in Pakistan

Akzo Nobel Invests in UK Innovation Hub

Germany’s AlzChem Postpones IPO

A Visible Turning Point for Oxea

Ten years ago, in March 2007, oxo chemicals producer Oxea was established as a buyout led by private-equity firm Advent International of oxo derivatives and oxo intermediates businesses from Celanese and European Oxo.

Pfizer and TVM Life Science Ventures Invest in Ixchelsis

Top Business Climate Meets Excellent Talent Pool

Brexit’s Implications for the UK’s Chemical Industry

EcoPhos in Egyptian Phosphate Venture

Novamont Starts Renewable BDO Plant

Merck KGaA Opens Darmstadt OLED Plant

ISPE Recognizes Leaders in Drug Shortage Prevention

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

LyondellBasell to Build PE Plant on US Gulf Coast

Shell Appalachia Project to Include 1.6 Million t of PE

Pembina and PIC Study Canadian PDH/PP Plant

Teijin Expands Capacity for Technora Fiber

After Pharma’s Patent Cliff

Sabuco Butanol Unit Ready to Go at Jubail

Chevron Phillips Expands Texas PAO Plant

Evonik Begins Silicones Project in China

Ineos Plans More Ethylene at Chocolate Bayou

Freeport Chosen for MEGlobal’s US Plant

BASF Petronas Breaks Ground on Malaysian HR-PIB Plant

Omya Opens Laboratory in Switzerland

Dottikon Boosts Swiss API Capacities

Perstorp Signs MoU for Indian Pentaerythritol Plant

Clariant Expands Global Masterbatch Capacity